Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + lonidamine
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cyclophosphamide, an alkylating agent, and lonidamine, a glycolytic inhibitor. Cyclophosphamide works by slowing or stopping the growth of cancer cells, while lonidamine acts on mitochondria and inhibits energy metabolism in cancer cells. This combination aims to enhance anticancer effects by targeting both conventional cell killing mechanisms and cancer-specific metabolic pathways.
02
Targets
SDH (Mitochondrial electron transport chain complex II)MPTP (Mitochondrial permeability transition pore)DNA
Beyond the preview
Go deeper on cyclophosphamide + lonidamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + lonidamine.